A Phase 3 study of a new drug regime for tuberculosis, which involved replacing the antibiotic moxifloxacin for one of two other drugs, failed to shorten the treatment time for the disease from six to four months. But the new regime was safe, according to the Global Alliance for TB Drug Development.
